OAB is a common finding in postmenopausal women. Hypoestrogenism is the root cause of many signs and symptoms of Genitourinary Syndrome of Menopause (vaginal dryness, atrophy, dyspareunia, urinary disorders, etc.
Genitourinary syndrome of menopause (GSM) is a hypoestrogenic condition with external genital, urological, and sexual implications that affects over 50% of postmenopausal women. Due to sexual embarrassment and the sensitive nature of discussing symptoms, GSM is greatly underdiagnosed.
To determine the prevalence of genitourinary syndrome of menopause (GSM) and urogynecological conditions associated with menopause, and to evaluate the impact of GSM on quality of life in a cohort of Spanish postmenopausal women.
The purpose of this article is to review the available data regarding the application and therapeutic outcomes of laser therapy for the treatment of genitourinary syndrome of menopause (GSM).
There have been several studies regarding the use of laser therapy for the treatment of GSM.
Laser therapy has a therapeutic role in various medical conditions and most recently has gained interest as a non-hormonal treatment for genitourinary syndrome of menopause (GSM) and as a non-invasive option for stress urinary incontinence (SUI).
To evaluate the long-term efficacy of a second generation of vaginal laser treatment, the vaginal erbium laser, as a non-ablative photothermal therapy for the management of genitourinary syndrome of menopause.
This technical bulletin reviews the evidence relating to risks and benefits of using intravaginal laser technology in the management of genitourinary syndrome of menopause and stress urinary incontinence.
More than 60% of people treated for cancer have long-term sexual dysfunction. However, fewer than 25% of those with sexual problems get help from a health professional. Although cancer-related sexual problems usually begin with physiological damage from cancer treatment, a patient's coping skills and the quality of the sexual relationship are crucial in sexual rehabilitation.
Androgens have been shown to exert beneficial effects on vaginal physiology, at least partially independent of their aromatization to estrogens. Androgen deficiency in the vagina and in the other genitourinary tissues contributes to the development of vulvovaginal atrophy and genitourinary syndrome of menopause, resulting in impaired arousal and lubrication and dyspareunia.
The major cause of urogenital atrophy in menopausal women is estrogen loss. The symptoms are usually progressive in nature and deteriorate with time from the menopausal transition. The most prevalent urogenital symptoms are vaginal dryness, vaginal irritation and itching.
Login to update email address, newsletter preferences and use bookmarks.